share_log

T2 Biosystems | 8-K: Entered into an Equity Distribution Agreement

T2 Biosystems | 8-K: Entered into an Equity Distribution Agreement

T2 Biosystems | 8-K:签订股权分销协议
美股SEC公告 ·  2024/07/20 04:21

Moomoo AI 已提取核心信息

T2 Biosystems announced the termination of its Equity Distribution Agreement with Canaccord Genuity LLC on July 19, 2024. The agreement, originally established on March 31, 2021, had enabled the company to sell shares of its common stock through an "at the market" equity offering program with Canaccord acting as sales agent.The company confirmed that no termination penalties are associated with ending the agreement. The termination was executed in accordance with the terms outlined in the original agreement, which was previously filed as Exhibit 1.2 to the Company's Registration Statement on Form S-3 with the SEC on March 31, 2021.
T2 Biosystems announced the termination of its Equity Distribution Agreement with Canaccord Genuity LLC on July 19, 2024. The agreement, originally established on March 31, 2021, had enabled the company to sell shares of its common stock through an "at the market" equity offering program with Canaccord acting as sales agent.The company confirmed that no termination penalties are associated with ending the agreement. The termination was executed in accordance with the terms outlined in the original agreement, which was previously filed as Exhibit 1.2 to the Company's Registration Statement on Form S-3 with the SEC on March 31, 2021.
T2 Biosystems于2024年7月19日宣布终止与Canaccord Genuity LLC的股权分配协议。该协议最初于2021年3月31日建立,使公司能够通过市场报价计划出售其普通股,Canaccord作为销售代理。 公司确认没有与终止协议相关的罚金。终止是根据原始协议中规定的条款执行的,该协议在2021年3月31日作为公司S-3表格注册声明的附件1.2提交给SEC。
T2 Biosystems于2024年7月19日宣布终止与Canaccord Genuity LLC的股权分配协议。该协议最初于2021年3月31日建立,使公司能够通过市场报价计划出售其普通股,Canaccord作为销售代理。 公司确认没有与终止协议相关的罚金。终止是根据原始协议中规定的条款执行的,该协议在2021年3月31日作为公司S-3表格注册声明的附件1.2提交给SEC。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息